Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation

Open access
Gómez-Ramírez, Susana, Brilli, Elisa, Tarantino, Germano, Muñoz, Manuel · 2018 · Pharmaceuticals

Abstract

Iron deficiency (ID) is usually treated with oral iron salts, but up to 50% of patients complain of gastrointestinal side effects, leading to reduced compliance with treatment. Intravenous (IV) iron formulations are increasingly safe, but there is still a risk of infusion, hypersensitivity reactions and the need for venous access and infusion monitoring. Sucrosomial® Iron (SI) is an innovative oral iron formulation in which ferric pyrophosphate is protected by a phospholipid bilayer plus a sucrester matrix (sucrosome), which is absorbed through para-cellular and trans-cellular routes (M cells). This confers SI’s unique structural, physicochemical and pharmacokinetic characteristics, together with its high iron bioavailability and excellent gastrointestinal tolerance. The analysis of the available evidence supports oral SI iron as a valid option for ID treatment, which is more efficacious and tolerable than oral iron salts. SI has also demonstrated a similar effectiveness, with lower risks, in patients usually receiving IV iron (e.g., chronic kidney disease, cancer, bariatric surgery). Thus, oral SI emerges as a valuable first option for treating ID, especially for subjects with intolerance to iron salts or those for whom iron salts are inefficacious. Moreover, SI should also be considered as an alternative to IV iron for initial and/or maintenance treatment in different patient populations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph11040097

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Prevalence of iron deficiency across pathologies. (Data taken from references [5,6,7,8,9,10,11,12,13]).
Figure 1 Prevalence of iron deficiency across pathologies. (Data taken from references [5,6,7,8,9,10,11,12,13]).CC BY · PubMed Central
Figure 2 Laboratory assessment of iron status. * Low reticulocyte Hb content (<28 pg), increased hypochromic red cells (>5%) or high soluble transferrin receptor to log ferritin ratio (>2) could identify a component of an absolute iron deficiency in the presence of an inflammation-induced high ferritin level.
Figure 2 Laboratory assessment of iron status. * Low reticulocyte Hb content (<28 pg), increased hypochromic red cells (>5%) or high soluble transferrin receptor to log ferritin ratio (>2) could identify a component of an absolute iron deficiency in the presence of an inflammation-induced high ferritin level.CC BY · PubMed Central
Figure 3 Schematic structure of Sucrosomial® iron.
Figure 3 Schematic structure of Sucrosomial® iron.CC BY · PubMed Central
Figure 4 Gastro-resistance and intestinal absorption of Sucrosomial® iron. (A) Gastro-resistant properties of Sucrosomial® iron compared to a sucrester-free iron preparation in an in-vitro simulated gastric fluid digestion at pH 1.2. (B) The involvement of M cells in Sucrosomial® iron uptake was evaluated using an in vitro CACO2/RajiB co-culture. The iron to protein ratio was significantly increased in co-culture cells treated with Sucrosomial® iron (SI), compared to other oral iron formulations: ferrous sulfate (FS), ferrous ascorbate (FeASC), ferrous ethylene-diamine-tetra-acetate (FeEDTA), ferrous bisglycinate (FeBIS), and control (no iron) (data are mean ± SEM, * p < 0.05) (Adapted from references [41,42]).
Figure 4 Gastro-resistance and intestinal absorption of Sucrosomial® iron. (A) Gastro-resistant properties of Sucrosomial® iron compared to a sucrester-free iron preparation in an in-vitro simulated gastric fluid digestion at pH 1.2. (B) The involvement of M cells in Sucrosomial® iron uptake was evaluated using an in vitro CACO2/RajiB co-culture. The iron to protein ratio was significantly increased in co-culture cells treated with Sucrosomial® iron (SI), compared to other oral iron formulations: ferrous sulfate (FS), ferrous ascorbate (FeASC), ferrous ethylene-diamine-tetra-acetate (FeEDTA), ferrous bisglycinate (FeBIS), and control (no iron) (data are mean ± SEM, * p < 0.05) (Adapted from references [41,42]).CC BY · PubMed Central
Figure 5 Bioavailability experiments on CACO-2 cells. Ferritin expression by cells treated with Sucrosomial® iron (SI) was significantly increased, compared to cells treated with ferrous sulfate (FS), phospholipid containing ferric pyrophosphate (Lipofer®), or micronized, dispersible ferric pyrophosphate (SunActive®) (A) or different iron salts, FS, ferric pyrophosphate (FePYR), ferrous ascorbate (FeASC), ferrous ethylene-diamine-tetra-acetate (FeEDTA), ferrous bisglycinate (FeBIS), and control (no iron) (B) (Data are mean ± SEM, * p < 0.001 SI vs. other iron compounds) (Adapted from references [41,45]).
Figure 5 Bioavailability experiments on CACO-2 cells. Ferritin expression by cells treated with Sucrosomial® iron (SI) was significantly increased, compared to cells treated with ferrous sulfate (FS), phospholipid containing ferric pyrophosphate (Lipofer®), or micronized, dispersible ferric pyrophosphate (SunActive®) (A) or different iron salts, FS, ferric pyrophosphate (FePYR), ferrous ascorbate (FeASC), ferrous ethylene-diamine-tetra-acetate (FeEDTA), ferrous bisglycinate (FeBIS), and control (no iron) (B) (Data are mean ± SEM, * p < 0.001 SI vs. other iron compounds) (Adapted from references [41,45]).CC BY · PubMed Central
Figure 6 Iron supplementation in anemic piglets and mice. (A) Hemoglobin concentration in anemic piglets treated with iron dextran (FeDEX) or Sucrosomial® iron (SI) (Data are mean ± SD; * p < 0.001, treatment vs. anemic; ** p < 0.001, SI vs. FeDEX). (B) Change in hemoglobin levels in anemic mice after a 14-day treatment with Sucrosomial® iron (SI) or ferrous sulfate (FS). (Data are mean ± SD; * p < 0.01, SI or FS vs. saline; ** p < 0.05, FS vs. vehicle) (Adapted from references [46,47]).
Figure 6 Iron supplementation in anemic piglets and mice. (A) Hemoglobin concentration in anemic piglets treated with iron dextran (FeDEX) or Sucrosomial® iron (SI) (Data are mean ± SD; * p < 0.001, treatment vs. anemic; ** p < 0.001, SI vs. FeDEX). (B) Change in hemoglobin levels in anemic mice after a 14-day treatment with Sucrosomial® iron (SI) or ferrous sulfate (FS). (Data are mean ± SD; * p < 0.01, SI or FS vs. saline; ** p < 0.05, FS vs. vehicle) (Adapted from references [46,47]).CC BY · PubMed Central
Figure 7 Comparative efficacy of different oral iron formulations for treating bleeding-induced moderate-to-severe anemia. SunActive®, micronized ferric pyrophosphate. Each oral iron formulation was tested in 60 patients (Data taken from reference [89]).
Figure 7 Comparative efficacy of different oral iron formulations for treating bleeding-induced moderate-to-severe anemia. SunActive®, micronized ferric pyrophosphate. Each oral iron formulation was tested in 60 patients (Data taken from reference [89]).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 81 references

Research works printed but not linked: 12

  1. 2017, Anaemia in the elderly, Med. Clin., 149, 496
  2. Starzynski, 2017, Comparison of the therapeutical potential of oral Sucrosomial® iron and parenteral iron dextran supplementations in neonatal iron deficiency anemia in pigs, Am. J. Hematol., 92, E286
  3. Brilli, E., Barnadas, R., Camacho, M., Giordano, G., and Tarantino, G. (2018, January 8–11). Sucrosomial® Iron Absorption Involves M Cells Interaction. Proceedings of the European Iron Club Annual Meeting, Zürich, Switzerland.
  4. Berardi, 2016, Efficacy of oral Sucrosomial® iron in puerperium anemia, Exp. Rev. Hematol., 9, 40
  5. Barni, 2017, Upfront use of Sucrosomial® iron prevents transfusions in cancer patients on chemotherapy, Support. Care Cancer, 25, S144
  6. Bastida, 2016, Efficacy and tolerability of Sucrosomial iron supplementation in IBD patients with iron deficiency anemia and intolerance to iron oral salts, Exp. Rev. Hematol., 9, 6
  7. Stuklov, N.I., Basiladze, I.G., Pivnik, A.V., Knyazev, O.V., and Parfenov, A.I. (2018). Characteristics and modern treatment of iron deficiency syndromes in inflammatory bowel diseases. Exp. Rev. Hematol., 10, in press.
  8. Farinati, F., and Maddalo, G. (2018). Iron and/or B12 deficient anemia in autoimmune gastritis. High dose sucrosomial iron supplementation: Preliminary data of a single center experience. Exp. Rev. Hematol., 10, in press.
  9. Shipton, 2018, Deficiencies of vitamin B12, folate and iron over 4 years of follow-up post-bariatric surgery [abstract], Br. J. Surg., 105, 28
  10. Karavidas, A., Trogkanis, E., Farmakis, D., Papingiotis, G., Matzaraki, V., Perpinia, A., and Parissis, J. (2018). Oral sucrosomial iron improves quality of life in heart failure patients with iron deficiency: A preliminary proof-of-concept study. Exp. Rev. Hematol., 10, in press.
  11. Cabrera, P., Gómez, S., Herrero, V., Martín, E., Pavía, J., and Muñoz, M. (2016, January 2–3). Prevalence and consequences of anaemia among patients hospitalised at the internal medicine ward: A single centre audit. Proceedings of the 15th European Congress of Internal Medicine, Amsterdam, The Netherlands.
  12. Giordano, 2016, Reduction of inflammatory markers with liposomal iron (Sideral®). Pre-clinical and clinical results, Exp. Rev. Hematol., 9, S17

Cited by

See all 132

Metadata

Authors
Gómez-Ramírez, S., Brilli, E., Tarantino, G., & Muñoz, M.
Affiliations
  • Department of Internal Medicine, University Hospital Virgen de la Victoria. Campus de Teatinos, 2010 Málaga, Spain
  • Scientific Department, Alesco S.r.l. Via delle Lenze, 216/B, 56122 Pisa, Italy
  • PharmaNutra SpA (Italy) (IT)
  • Perioperative Transfusion Medicine, Department of Surgical Specialties, Biochemistry and Immunology, School of Medicine, Campus de Teatinos, 29071 Málaga, Spain
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2018-10-04
Volume
11
Issue
4
Pages
97
ISSN
1424-8247 (ISSN-L)
OpenAlex
W2895639972
Cited by
132
References
81
Citations by year
2026: 13 · 2025: 12 · 2024: 28 · 2023: 19 · 2022: 14 · 2021: 20 · 2020: 17 · 2019: 7 · 2018: 1
FWCI
1.86
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Keywords
sucrosomial iron, oral iron supplementation, iron deficiency, ferric pyrophosphate, phospholipid bilayers, M cells, iron bioavailability, gastrointestinal tolerance, chronic kidney disease, cancer patients, bariatric surgery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation. https://app.cochat.ai/papers/10.3390/ph11040097
The paper
Gómez-Ramírez, S., Brilli, E., Tarantino, G., & Muñoz, M. (2018). Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation. Pharmaceuticals. https://doi.org/10.3390/ph11040097

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.